Skip to main content

Articles

Page 1 of 39

  1. To evaluate the effects of cardiac resynchronization therapy (CRTd) in patients with type 2 diabetes mellitus (T2DM) optimized via automatic vs. echocardiography-guided approach.

    Authors: Celestino Sardu, Pasquale Paolisso, Valentino Ducceschi, Matteo Santamaria, Cosimo Sacra, Massimo Massetti, Antonio Ruocco and Raffaele Marfella

    Citation: Cardiovascular Diabetology 2020 19:202

    Content type: Original investigation

    Published on:

  2. Currently available treatments have only been partly successful in patients with severe hypertriglyceridemia, including those with high serum triglycerides above 1,000 mg/dL (11.3 mmol/L), who often suffer fro...

    Authors: Chie Iitake, Daisaku Masuda, Masahiro Koseki and Shizuya Yamashita

    Citation: Cardiovascular Diabetology 2020 19:201

    Content type: Original investigation

    Published on:

  3. Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal ou...

    Authors: João Pedro Ferreira, Subodh Verma, David Fitchett, Anne Pernille Ofstad, Sabine Lauer, Isabella Zwiener, Jyothis George, Christoph Wanner, Bernard Zinman and Silvio E. Inzucchi

    Citation: Cardiovascular Diabetology 2020 19:200

    Content type: Original investigation

    Published on:

  4. The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor agon...

    Authors: Gilles R. Dagenais, Lars Rydén, Lawrence A. Leiter, Mark Lakshmanan, Leanne Dyal, Jeffrey L. Probstfield, Charles Messan Atisso, Jonathan E. Shaw, Ignacio Conget, William C. Cushman, Patricio Lopez-Jaramillo, Fernando Lanas, Ernesto German Cordona Munoz, Valdis Pirags, Nana Pogosova, Jan Basile…

    Citation: Cardiovascular Diabetology 2020 19:199

    Content type: Original investigation

    Published on:

  5. Metformin has been shown to have various cardiovascular benefits beyond its antihyperglycemic effects, including a reduction in stroke, heart failure, myocardial infarction, cardiovascular death, and all-cause...

    Authors: Teerapat Nantsupawat, Wanwarang Wongcharoen, Siriporn C. Chattipakorn and Nipon Chattipakorn

    Citation: Cardiovascular Diabetology 2020 19:198

    Content type: Review

    Published on:

  6. The relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, although with conflicting results. Type 2 diabetes mellitus (T2DM) is...

    Authors: Mei-Zhen Wu, Chi-Ho Lee, Yan Chen, Shuk-Yin Yu, Yu-Juan Yu, Qing-Wen Ren, Ho-Yi Carol Fong, Pui-Fai Wong, Hung-Fat Tse, Siu-Ling Karen Lam and Kai-Hang Yiu

    Citation: Cardiovascular Diabetology 2020 19:197

    Content type: Original investigation

    Published on:

  7. Approximately half of all patients with type 2 diabetes (T2D) develop a certain degree of renal impairment. In many of them, chronic kidney disease (CKD) progresses over time, eventually leading to end-stage k...

    Authors: Francesco Giorgino, Jiten Vora, Peter Fenici and Anna Solini

    Citation: Cardiovascular Diabetology 2020 19:196

    Content type: Review

    Published on:

  8. We aimed to investigate the association of metabolic syndrome (MetS) and its single components with cardiovascular risk and estimated their impact on the prematurity of occurrence of cardiovascular events usin...

    Authors: María J. Guembe, Cesar I. Fernandez-Lazaro, Carmen Sayon-Orea, Estefanía Toledo and Conchi Moreno-Iribas

    Citation: Cardiovascular Diabetology 2020 19:195

    Content type: Original investigation

    Published on:

  9. The prevalence of peripheral artery disease (PAD) is obviously increased in patients with diabetes. Existing evidence shows that cysteine-rich angiogenic inducer 61 (Cyr61), a 40-kD secreted protein, plays imp...

    Authors: Bin Feng, Guidong Xu, Kangyun Sun, Kaipeng Duan, Bimin Shi and Nannan Zhang

    Citation: Cardiovascular Diabetology 2020 19:194

    Content type: Original investigation

    Published on:

  10. Type 2 Diabetes Mellitus (T2DM) is a well-known comorbidity to COVID-19 and coagulopathies are a common accompaniment to both T2DM and COVID-19. In addition, patients with COVID-19 are known to develop micro-c...

    Authors: Etheresia Pretorius, Chantelle Venter, Gert Jacobus Laubscher, Petrus Johannes Lourens, Janami Steenkamp and Douglas B. Kell

    Citation: Cardiovascular Diabetology 2020 19:193

    Content type: Original investigation

    Published on:

  11. Type 2 diabetes mellitus (T2DM) is associated with an increased cardiovascular risk related at least in part to a more vulnerable plaque phenotype. However, patients with T2DM exhibit also an increased risk fo...

    Authors: Rosalia Dettori, Andrea Milzi, Kathrin Burgmaier, Mohammad Almalla, Martin Hellmich, Nikolaus Marx, Sebastian Reith and Mathias Burgmaier

    Citation: Cardiovascular Diabetology 2020 19:192

    Content type: Original investigation

    Published on:

  12. The “obesity paradox” has not been elucidated in the long-term outcomes of acute coronary syndrome (ACS). We investigated the association between obesity and cardiovascular (CV) outcomes in ACS patients with a...

    Authors: Se-Jun Park, Kyoung Hwa Ha and Dae Jung Kim

    Citation: Cardiovascular Diabetology 2020 19:191

    Content type: Original investigation

    Published on:

  13. The well-established benefit of Low-Dense-Lipoprotein-cholesterol (LDL-c) lowering treatments (LLTs) has led clinical guidelines to lower the cardiovascular prevention targets. Despite this, there is a surpris...

    Authors: Mario Luca Morieri, Angelo Avogaro and Gian Paolo Fadini

    Citation: Cardiovascular Diabetology 2020 19:190

    Content type: Original investigation

    Published on:

  14. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has shown evidence of cardiovascular benefit in patients with type 2 diabetes mellitus (T2DM). Currently metformin is the guideline-recommended first-line tr...

    Authors: Tien-Hsing Chen, Yan-Rong Li, Shao-Wei Chen, Yu-Sheng Lin, Chi-Chin Sun, Dong-Yi Chen, Chun-Tai Mao, Michael Wu, Chih-Hsiang Chang, Pao-Hsien Chu and Victor Chien-Chia Wu

    Citation: Cardiovascular Diabetology 2020 19:189

    Content type: Original investigation

    Published on:

  15. Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i ...

    Authors: Ann Wan-Chin Ling, Cze-Ci Chan, Shao-Wei Chen, Yi-Wei Kao, Chien-Ying Huang, Yi-Hsin Chan and Pao-Hsien Chu

    Citation: Cardiovascular Diabetology 2020 19:188

    Content type: Original investigation

    Published on:

  16. Depression and cardiovascular disease (CVD) are among the most common causes of disability in high-income countries, depression being associated with a 30% increased risk of future CV events. Depression is twi...

    Authors: C. Macchi, C. Favero, A. Ceresa, L. Vigna, D. M. Conti, A. C. Pesatori, G. Racagni, A. Corsini, N. Ferri, C. R. Sirtori, M. Buoli, V. Bollati and M. Ruscica

    Citation: Cardiovascular Diabetology 2020 19:187

    Content type: Original investigation

    Published on:

  17. The association between alkaline phosphatase (ALP) and incident diabetes remains uncertain. Our study aimed to investigate the prospective relation of serum ALP with the risk of new-onset diabetes, and explore...

    Authors: Yuanyuan Zhang, Chun Zhou, Jianping Li, Yan Zhang, Di Xie, Min Liang, Binyan Wang, Yun Song, Xiaobin Wang, Yong Huo, Fan Fan Hou, Xiping Xu and Xianhui Qin

    Citation: Cardiovascular Diabetology 2020 19:186

    Content type: Original investigation

    Published on:

  18. The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at ...

    Authors: Guntram Schernthaner, Naim Shehadeh, Alexander S. Ametov, Anna V. Bazarova, Fahim Ebrahimi, Peter Fasching, Andrej Janež, Péter Kempler, Ilze Konrāde, Nebojša M. Lalić, Boris Mankovsky, Emil Martinka, Dario Rahelić, Cristian Serafinceanu, Jan Škrha, Tsvetalina Tankova…

    Citation: Cardiovascular Diabetology 2020 19:185

    Content type: Commentary

    Published on:

  19. Cardiovascular magnetic resonance imaging (CMR) have described localised non-ischemic late gadolinium enhancement (LGE) lesions of prognostic importance in various non-ischemic cardiomyopathies. Ischemic LGE l...

    Authors: Annemie Stege Bojer, Martin Heyn Sørensen, Niels Vejlstrup, Jens P. Goetze, Peter Gæde and Per Lav Madsen

    Citation: Cardiovascular Diabetology 2020 19:184

    Content type: Original investigation

    Published on:

  20. High-sensitivity C-reactive protein (hs-CRP) elevation frequently occurs in acute myocardial infarction (AMI) and is associated with adverse outcomes. Since diabetes mellitus (DM) is characterized by an underl...

    Authors: Claudia Lucci, Nicola Cosentino, Stefano Genovese, Jeness Campodonico, Valentina Milazzo, Monica De Metrio, Maurizio Rondinelli, Daniela Riggio, Maria Luisa Biondi, Mara Rubino, Katia Celentano, Alice Bonomi, Nicolò Capra, Fabrizio Veglia, Piergiuseppe Agostoni, Antonio L. Bartorelli…

    Citation: Cardiovascular Diabetology 2020 19:183

    Content type: Original investigation

    Published on:

  21. The global epidemic of diabetes mellitus continues to grow and affects developed and developing countries alike. Intensive glycemic control is thought to modify the risks for vascular complications, hence the ...

    Authors: Wei Ling, Yi Huang, Yan-Mei Huang, Rong-Rong Fan, Yi Sui and Hai-Lu Zhao

    Citation: Cardiovascular Diabetology 2020 19:182

    Content type: Original investigation

    Published on:

  22. Little is known about age-specific target blood pressure (BP) in hypertensive patients with diabetes mellitus (DM). The aim of this study was to determine the BP level at the lowest cardiovascular risk of hype...

    Authors: Hack-Lyoung Kim, Hyue Mee Kim, Chang Hee Kwon, Jeong-Hun Shin, Mi-Hyang Jung, Chan Joo Lee, Dae-Hee Kim, Woo-Hyeun Kim, Si-Hyuck Kang, Ju-Hee Lee, In Jeong Cho, Iksung Cho, Jun Hyeok Lee, Dae Ryong Kang, Hae-Young Lee, Wook-Jin Chung…

    Citation: Cardiovascular Diabetology 2020 19:181

    Content type: Original investigation

    Published on:

  23. Mid-regional pro-atrial natriuretic peptide (MR-proANP) is a useful biomarker in outpatients with type 2 diabetes (T2D) to diagnose heart failure (HF). Elevated B-type natriuretic peptides are included in the ...

    Authors: Jesper Jensen, Morten Schou, Caroline Kistorp, Jens Faber, Tine W. Hansen, Magnus T. Jensen, Henrik U. Andersen, Peter Rossing, Tina Vilsbøll and Peter G. Jørgensen

    Citation: Cardiovascular Diabetology 2020 19:180

    Content type: Original investigation

    Published on:

  24. Patients with both diabetes mellitus (DM) and chronic kidney disease (CKD) are a subpopulation characterized by ultrahigh ischemic and bleeding risk after percutaneous coronary intervention. There are limited ...

    Authors: Chao Gao, Mariusz Tomaniak, Kuniaki Takahashi, Hideyuki Kawashima, Rutao Wang, Hironori Hara, Masafumi Ono, Gilles Montalescot, Scot Garg, Michael Haude, Ton Slagboom, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Robert-Jan van Geuns, Christian Hamm…

    Citation: Cardiovascular Diabetology 2020 19:179

    Content type: Original investigation

    Published on:

  25. High N-terminal pro-brain-type natriuretic peptide levels have been associated with a lower risk of type 2 diabetes mellitus (T2D). However, less is known about other cardiac stress biomarkers in this context....

    Authors: Chaterina Sujana, Jochen Seissler, Jens Jordan, Wolfgang Rathmann, Wolfgang Koenig, Michael Roden, Ulrich Mansmann, Christian Herder, Annette Peters, Barbara Thorand and Cornelia Then

    Citation: Cardiovascular Diabetology 2020 19:178

    Content type: Original investigation

    Published on:

  26. The epidemiology of diabetes and idiopathic cardiomyopathy have limited data. We investigated the overall and the age-, sex-, and urbanization-specific incidence and relative hazard of idiopathic cardiomyopath...

    Authors: Hua-Fen Chen, Ya-Hui Chang, Hsien-Jung Lo, Muhammad Atoillah Isfandiari, Santi Martini, Wen-Hsuan Hou and Chung-Yi Li

    Citation: Cardiovascular Diabetology 2020 19:177

    Content type: Original investigation

    Published on:

  27. Glucose variability has been associated with cardiovascular outcomes in type 2 diabetes, however, the interplay between glucose variability, empagliflozin and cardiovascular death has not been explored. In the...

    Authors: Antonio Ceriello, Anne Pernille Ofstad, Isabella Zwiener, Stefan Kaspers, Jyothis George and Antonio Nicolucci

    Citation: Cardiovascular Diabetology 2020 19:176

    Content type: Original investigation

    Published on:

  28. The relationship between blood pressure and mortality in type 2 diabetes (T2DM) is controversial, with concern for increased risk associated with excessively lowered blood pressure.

    Authors: Magnus O. Wijkman, Brian Claggett, Rafael Diaz, Hertzel C. Gerstein, Lars Køber, Eldrin Lewis, Aldo P. Maggioni, Emil Wolsk, David Aguilar, Rhonda Bentley-Lewis, John J. McMurray, Jeffrey Probstfield, Matthew Riddle, Jean-Claude Tardif, Scott D. Solomon and Marc A. Pfeffer

    Citation: Cardiovascular Diabetology 2020 19:175

    Content type: Original investigation

    Published on:

  29. We compared the risk of bleeding and cardiovascular disease (CVD) events between non-vitamin K antagonist oral anticoagulant (NOAC) and warfarin in people with type 2 diabetes (T2DM).

    Authors: Dahai Yu, Zhanzheng Zhao and David Simmons

    Citation: Cardiovascular Diabetology 2020 19:174

    Content type: Original investigation

    Published on:

  30. Peripheral artery disease (PAD) in the lower extremities is a common complication of type 2 diabetes and has been shown to be associated with mortality. The ankle-brachial index (ABI) is a simple noninvasive m...

    Authors: Yu-Hsuan Li, Wayne Huey-Herng Sheu and I-Te Lee

    Citation: Cardiovascular Diabetology 2020 19:173

    Content type: Original investigation

    Published on:

  31. Head-to-head comparison of clinical effectiveness between dulaglutide and liraglutide in Asia is limited. This study was aimed to assess the real-world comparative effectiveness of dulaglutide versus liraglutide.

    Authors: Kai-Cheng Chang, Shih-Chieh Shao, Shihchen Kuo, Chen-Yi Yang, Hui-Yu Chen, Yuk-Ying Chan and Huang-Tz Ou

    Citation: Cardiovascular Diabetology 2020 19:172

    Content type: Original investigation

    Published on:

  32. Glycated albumin (GA) is a marker of short-term glycemic control and is strongly associated with the occurrence of diabetes. Previous studies have shown an association between GA and the effect of clopidogrel ...

    Authors: Xiliang Zhao, Quan Li, Chenchen Tu, Yong Zeng and Yicong Ye

    Citation: Cardiovascular Diabetology 2020 19:171

    Content type: Original investigation

    Published on:

  33. Cardiovascular complications represent the major cause of morbidity and mortality of type 2 diabetes mellitus (T2DM) patients. In particular, peripheral artery disease (PAD) represents a frequent T2DM vascular...

    Authors: Federico Biscetti, Elisabetta Nardella, Maria Margherita Rando, Andrea Leonardo Cecchini, Flavia Angelini, Alessandro Cina, Roberto Iezzi, Marco Filipponi, Angelo Santoliquido, Dario Pitocco, Raffaele Landolfi and Andrea Flex

    Citation: Cardiovascular Diabetology 2020 19:170

    Content type: Original investigation

    Published on:

  34. Exercise is a well-accepted strategy to improve lipid and inflammatory profile in individuals with type 2 diabetes (T2DM). However, the exercise intensity having the most benefits on lipids and inflammatory ma...

    Authors: João P. Magalhães, Diana A. Santos, Inês R. Correia, Megan Hetherington-Rauth, Rogério Ribeiro, João F. Raposo, Andreia Matos, Manuel D. Bicho and Luís B. Sardinha

    Citation: Cardiovascular Diabetology 2020 19:169

    Content type: Original investigation

    Published on:

  35. We assessed in a nationwide cohort the association between adolescent BMI and early-onset (< 40 years) type 2 diabetes among Israelis of Ethiopian origin.

    Authors: Maya Simchoni, Uri Hamiel, Orit Pinhas-Hamiel, Inbar Zucker, Tali Cukierman-Yaffe, Miri Lutski, Estela Derazne, Zivan Beer, Doron Behar, Lital Keinan-Boker, Ofri Mosenzon, Dorit Tzur, Arnon Afek, Amir Tirosh, Itamar Raz and Gilad Twig

    Citation: Cardiovascular Diabetology 2020 19:168

    Content type: Original investigation

    Published on:

  36. Whether plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels is a predictor for cardiovascular outcomes has currently been controversial. No data is currently available regarding the relation of...

    Authors: Jia Peng, Ming-Ming Liu, Jing-Lu Jin, Ye-Xuan Cao, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Qian Dong, Jing Sun, Rui-Xia Xu and Jian-Jun Li

    Citation: Cardiovascular Diabetology 2020 19:167

    Content type: Original investigation

    Published on:

  37. Patients with type 1 diabetes (T1D) have higher mortality risk compared to the general population; this is largely due to increased rates of cardiovascular disease (CVD). As accurate CVD risk stratification is...

    Authors: Nicola Tecce, Maria Masulli, Roberta Lupoli, Giuseppe Della Pepa, Lutgarda Bozzetto, Luisa Palmisano, Angela Albarosa Rivellese, Gabriele Riccardi and Brunella Capaldo

    Citation: Cardiovascular Diabetology 2020 19:166

    Content type: Original investigation

    Published on:

  38. Several studies compared everolimus-eluting bioresorbable scaffolds (EE-BRS) with everolimus-eluting stents (EES), but only few assessed these devices in patients with diabetes mellitus.

    Authors: T. M. Hommels, R. S. Hermanides, B. Berta, E. Fabris, G. De Luca, E. H. Ploumen, C. von Birgelen and E. Kedhi

    Citation: Cardiovascular Diabetology 2020 19:165

    Content type: Original investigation

    Published on:

  39. Cardiometabolic disorders may worsen Covid-19 outcomes. We investigated features and Covid-19 outcomes for patients with or without diabetes, and with or without cardiometabolic multimorbidity.

    Authors: Ernesto Maddaloni, Luca D’Onofrio, Francesco Alessandri, Carmen Mignogna, Gaetano Leto, Giuseppe Pascarella, Ivano Mezzaroma, Miriam Lichtner, Paolo Pozzilli, Felice Eugenio Agrò, Monica Rocco, Francesco Pugliese, Andrea Lenzi, Rury R. Holman, Claudio Maria Mastroianni and Raffaella Buzzetti

    Citation: Cardiovascular Diabetology 2020 19:164

    Content type: Original investigation

    Published on:

  40. Adults with obesity and type 2 diabetes mellitus (T2DM) related to obesity are at increased risk of heart failure with preserved ejection fraction (HFpEF). Whether left ventricular (LV) diastolic function abno...

    Authors: Jeremy M. Steele, Elaine M. Urbina, Wojciech M. Mazur, Philip R. Khoury, Sherif F. Nagueh, Justin T. Tretter and Tarek Alsaied

    Citation: Cardiovascular Diabetology 2020 19:163

    Content type: Original investigation

    Published on:

  41. Diabetes mellitus is a risk for increased incidence of adverse clinical events after percutaneous coronary intervention. However, the difference in the incidence of adverse clinical events according to stent t...

    Authors: Ryota Kakizaki, Yoshiyasu Minami, Masahiro Katamine, Aritomo Katsura, Yusuke Muramatsu, Takuya Hashimoto, Kentaro Meguro, Takao Shimohama and Junya Ako

    Citation: Cardiovascular Diabetology 2020 19:162

    Content type: Original investigation

    Published on:

  42. Type 2 diabetes mellitus (T2DM) increases the risks of heart failure and mortality in patients with hypertension, however the underlying mechanism is unclear. This study aims to investigate the impact of coexi...

    Authors: Xue-Ming Li, Li Jiang, Ying-Kun Guo, Yan Ren, Pei-Lun Han, Li-Qing Peng, Rui Shi, Wei-Feng Yan and Zhi-Gang Yang

    Citation: Cardiovascular Diabetology 2020 19:161

    Content type: Original investigation

    Published on:

  43. Whether sodium glucose co-transporter 2 inhibitors (SGLT2i) are associated with a lower risk of cardiovascular as well as adverse lower limb events in patients with type-2 diabetes mellitus (T2DM) and concomit...

    Authors: Hsin-Fu Lee, Shao-Wei Chen, Jia-Rou Liu, Pei-Ru Li, Lung-Sheng Wu, Shang-Hung Chang, Yung-Hsin Yeh, Chi-Tai Kuo, Yi-Hsin Chan and Lai-Chu See

    Citation: Cardiovascular Diabetology 2020 19:160

    Content type: Original investigation

    Published on:

  44. Whereas selective sodium-glucose cotransporter 2 (SGLT2) inhibitors consistently showed cardiovascular protective effects in large outcome trials independent of the presence of type 2 diabetes mellitus (T2DM),...

    Authors: Alex Ali Sayour, Attila Oláh, Mihály Ruppert, Bálint András Barta, Eszter Mária Horváth, Kálmán Benke, Miklós Pólos, István Hartyánszky, Béla Merkely and Tamás Radovits

    Citation: Cardiovascular Diabetology 2020 19:159

    Content type: Original investigation

    Published on:

  45. The biomarker fibroblast growth factor-23 (FGF-23) has been associated with increased cardiovascular morbidity and mortality in both patients with and without type 2 diabetes. The aim of this study was to eval...

    Authors: Martin H. Sørensen, Annemie S. Bojer, Niklas R. Jørgensen, David A. Broadbent, Sven Plein, Per L. Madsen and Peter Gæde

    Citation: Cardiovascular Diabetology 2020 19:158

    Content type: Original investigation

    Published on:

  46. Diabetes is an independent risk factor for atrial fibrillation (AF), which is associated with increases in mortality and morbidity, as well as a diminished quality of life. Renal involvement in diabetes is com...

    Authors: Nam Ju Heo, Sang Youl Rhee, Jill Waalen and Steven Steinhubl

    Citation: Cardiovascular Diabetology 2020 19:157

    Content type: Original investigation

    Published on:

  47. Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations. Two cardiovascular (CV) outcomes trials showed that in subjec...

    Authors: Mansoor Husain, Stephen C. Bain, Anders Gaarsdal Holst, Thomas Mark, Søren Rasmussen and Ildiko Lingvay

    Citation: Cardiovascular Diabetology 2020 19:156

    Content type: Original investigation

    Published on:

  48. To investigate whether the Triglyceride-Glucose index (TyG-index) is associated with increased risk of cardiovascular diseases (CVD)/coronary heart disease (CHD).

    Authors: Niloofar Barzegar, Maryam Tohidi, Mitra Hasheminia, Fereidoun Azizi and Farzad Hadaegh

    Citation: Cardiovascular Diabetology 2020 19:155

    Content type: Original investigation

    Published on:

  49. We explored whether clinically relevant baseline characteristics of patients with type 2 diabetes can modify the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) or sodium-glucose cotransporter-2...

    Authors: Elvira D’Andrea, Aaron S. Kesselheim, Jessica M. Franklin, Emily H. Jung, Spencer Phillips Hey and Elisabetta Patorno

    Citation: Cardiovascular Diabetology 2020 19:154

    Content type: Original investigation

    Published on:

  50. Metabolic syndrome (MetS) status changes over time, but few studies have investigated the relationship between the extent or duration of exposure to MetS and the risk of cardiovascular disease (CVD). We invest...

    Authors: Eun Young Lee, Kyungdo Han, Da Hye Kim, Yong-Moon Park, Hyuk-Sang Kwon, Kun-Ho Yoon, Mee Kyoung Kim and Seung-Hwan Lee

    Citation: Cardiovascular Diabetology 2020 19:153

    Content type: Original investigation

    Published on:

Annual Journal Metrics